Background. Azithromycin in combination with sulphonamides is active against Pneumocystis carinii (PCP) in animals. We assessed the clinical efficacy of azithromycin for PCP prophylaxis in human beings.
The fungal pathogen Pneumocystis carinii was first depatients have suggested, regardless of the nature of the underlying immunosuppression, that glucocorticoids scribed by Chagas in 1909 but its clinical importance was not recognised until 1951when it was identified as are an independent risk factor for development of P carinii pneumonia. 2 5 the cause of interstitial plasma cell pneumonia, which had been described in Europe in the late 1930s and In HIV infected patients the CD4+ T lymphocyte count is used in clinical practice both to determine the 1940s in premature and malnourished children. In the 1960s P carinii pneumonia occurred mainly in children risk of P carinii pneumonia in an individual patient and to make recommendations about when to start with congenital defects of the immune system and in both adults and children with acquired immune defects prophylaxis (see below). [6] [7] [8] [9] [10] There is increasing evidence that the CD4+ T lymphocyte count may also be useful due to malignancy or its treatment. 1 2 With the advent of organ transplantation, it became clear that P carinii in determining whether non-HIV infected immunosuppressed individuals are at risk of P carinii pneumonia was associated with the immunosuppression used to prevent organ rejection. With prophylaxis, case pneumonia. 11 12 rates fell in these populations. In 1980 P carinii pneumonia was the first opportunistic infection to be associated with HIV infection, and the AIDS pandemic Who should receive prophylaxis? was defined. 3 The United States Public Health Service and the Infectious Diseases Society of America have made the following recommendations.
HIV infected patients, including those who are pregWho gets P carinii pneumonia? Most cases of P carinii pneumonia occur in patients with nant and those receiving combination antiretroviral therapy (also known as highly active antiretroviral therapy abnormalities of T lymphocyte function or numbers: P carinii pneumonia rarely occurs in patients with isolor HAART), should receive primary prophylaxis against P carinii pneumonia if they have a CD4+ T lymphocyte ated B cell defects. Before the introduction of prophylaxis, attack rates for P carinii pneumonia varied count of <200 cells/ l or a history of oral/pharyngeal candidiasis. 10 Prophylaxis should also be given to from 22-43% in children with acute lymphoblastic leukaemia 2 4 and 27-42% in children with severe patients who have a CD4+ T lymphocyte count which is <14% of the total lymphocyte count or a history combined immunodeficiency, to 25% in those with rhabdomyosarcoma. 2 4 In patients who do not receive of an AIDS defining illness -for example, Kaposi's sarcoma. 10 If it is not possible to monitor the CD4+ prophylaxis after organ transplantation, attack rates for P carinii pneumonia vary from 4-10% following renal T lymphocyte count frequently (at least every three months), then consideration should be given to starting transplantation to 16-43% following heart or heart/lung transplantation. 2 4 Several studies in non-HIV infected prophylaxis in patients whose CD4+ T lymphocyte counts are between 200 and 250 cells/ l. 10 13 Secondary factors in longer survival. 25 It is important to remember that these benefits from prophylaxis were reported beprophylaxis should be given to all HIV infected patients who have had an episode of P carinii pneumonia, refore the advent of HAART. gardless of their CD4+ T lymphocyte count. Although HAART may cause a rise in the CD4+ T lymphocyte count to >200 cells/ l, there are insufficient data to What are the costs of prophylaxis?
The cost of prophylaxis varies considerably from £20 recommend stopping secondary prophylaxis against P carinii pneumonia (see below).
10
(US$60) per year for co-trimoxazole to £6346 (US$10 647) per year for atovaquone. In the non-HIV infected immunosuppressed population, those with high attack rates for P carinii pneumonia should receive prophylaxis. 2 Sepkowitz et al have suggested that, in addition, patients with any immune What adverse events are associated with prophylaxis? dysfunction induced by an inflammatory disease or by radiotherapy or chemotherapy who receive 20 mg/day Adverse reactions to co-trimoxazole, consisting of rash and/or fever, occur more commonly in patients immunoof prednisolone (or equivalent) should receive prophylaxis. 4 14 suppressed by HIV infection than in those immunosuppressed by other causes or those with normal immunity. 26 An explanation for this difference is not apparent. Hypotheses include HIV induced immunoWhat drug regimen is preferred for prophylaxis?
pathogenic effects or changes in acetylator dependent Co-trimoxazole 960 mg once daily is the regimen of metabolism of co-trimoxazole to toxic (hydroxylamine) choice for prophylaxis of P carinii pneumonia in both metabolites. 27 Desensitisation to co-trimoxazole should HIV infected and non-HIV infected immunosuppressed be attempted before considering a change to alternative, individuals.
9 10 15 Alternative agents which, in HIV inless effective prophylaxis.
28 29 fected patients, have been shown to be less effective include dapsone (with or without pyrimethamine), 16 nebulised pentamidine, 17 and atovaquone.
18
What effect does long term prophylaxis have on The ideal agent for prophylaxis is cheap, readily other pathogens? available, effective, easily administered so that comAs co-trimoxazole is a potent broad spectrum antipliance is maintained, has low toxicity, and does not bacterial agent in addition to being the most effective interact adversely with HAART or chemotherapy/ agent for prophylaxis of P carinii pneumonia, concerns immunosuppressive drug regimens. An additional benehave been expressed that its widespread long term use fit would be for it to provide "cross prophylaxis" against may lead to selection of resistance in bacteria. Until other micro-organisms. Cross prophylaxis is demrecently, once prophylaxis with co-trimoxazole was onstrated clearly for co-trimoxazole at a dose of 960 mg started, it was recommended that it should be used for once daily. In addition to effectively preventing P carinii the rest of the HIV infected person's life. It has been pneumonia, co-trimoxazole also protects against suggested that resistant bacteria might develop in these cerebral toxoplasmosis 17 19 and some bacterial individuals and subsequently spread into the general infections. 17 20 Lower doses of co-trimoxazole such as population. In the non-HIV infected population there 480 mg once daily 21 or 960 mg three times a week 22 are is already evidence that co-trimoxazole, used as proalso effective regimens for prophylaxis and may also phylaxis in patients with acute leukaemia, may induce confer cross prophylaxis. Immunosuppressed HIV nonplasmid type resistance in Enterobacteriaceae. 30 In infected patients with antibodies to Toxoplasma gondi patients with HIV infection the use of co-trimoxazole has should not receive nebulised pentamidine as prophylaxis been associated with the development of co-trimoxazole because of the risk of development of cerebral resistant Streptococcus pneumoniae. A serial cross sectional study from San Francisco General Hospital, USA has examined rates of resistance to co-trimoxazole among isolates of Staphylococcus aureus and also among seven common genera of the EnteroWhat are the long term benefits of prophylaxis? The widespread availability and uptake of co-tribacteriaceae (including Escherichia coli and Klebsiella spp) from HIV infected and non-infected inpatients and moxazole and other agents as prophylaxis has had a major impact on the incidence of P carinii pneumonia.
outpatients. 33 The study period was from 1988 until 1995. At the start of the study period co-trimoxazole In one study in London P carinii pneumonia accounted for 23% of all admissions to a specialist HIV unit in was not commonly used as nebulised pentamidine was the preferred option for prophylaxis, but co-trimoxazole 1986-7 (before prophylaxis was used) but was responsible for only 13% of admissions in 1990-1 (by subsequently became first choice for prophylaxis. Overall resistance rates (in all eight genera combined) were which time prophylaxis had been introduced).
23 Using data from 90 HIV centres in the USA, the Centres between 2.8% and 5.5% before 1988 and have risen steadily from 7.2% in 1988 to 20.4% in 1995. 33 This for Disease Control and Prevention, Atlanta found a reduction in the incidence of P carinii pneumonia from trend was most apparent among HIV infected patients in whom overall resistance increased from 6.3% in 1988 9.0 per 100 person years in 1991 to 5.3 per 100 person years in 1996. 24 Prophylaxis has also had an impact on to 53% in 1995. The largest increases in resistance were in isolates of S aureus (from 0% in 1988 to 48% in survival time in patients with HIV infection and CD4+ T lymphocyte counts of <200 cells/ l. In a study from 1995) and E coli (from 24% to 74%) from HIV infected patients. These data have implications for the clinician, San Francisco the median survival increased from 28.4 months in patients studied between 1983 and 1986 to as the long term benefit of co-trimoxazole needs to be balanced against its effect on resistance. Despite the 38.1 months in those studied between 1988 and 1993. 25 The largest increase in survival time was seen in those limitations of this study (it did not control for possible influences of concomitant therapies and the study who had P carinii pneumonia, suggesting that prophylaxis and treatment of this infection were important groups were incompletely defined), its findings have led to a reduction in the use of co-trimoxazole for "mutant" DHPS P carinii pneumonia were three times more likely to die than those with "wild type" (hazard prophylaxis and treatment of infections other than P carinii pneumonia at San Francisco General Hospital. 33 ratio=3.1; 95% CI 1.2 to 8.1).
41
Of note, DHPS mutations were not always associated with a failure to respond to co-trimoxazole as high dose co-trimoxazole was successful in 12 of 19 episodes Can P carinii become resistant to prophylaxis? Conventional methods of determining drug resistance with "mutant" DHPS. 41 This observation suggests that strains of P carinii with only one or two DHPS mutations cannot be used to answer this question as human derived P carinii cannot be cultured reliably in vitro. The drug are only partially resistant to sulpha drugs. 40 In E coli mutations in DHPS are associated with a low level target for sulphamethoxazole (and for dapsone, which is a sulphone) is dihydropterate synthase (DHPS) and of resistance to sulpha drugs; as additional mutations accumulate, high level resistance develops. 42 It is confor trimethoprim is dihydrofolate reductase (DHFR); these are sequential enzymes in the metabolism of folate.
ceivable that the same phenomena may be occurring in P carinii. In several bacteria, including E coli, Neisseria meningitidis, and S pneumoniae, and in the protozoan Plasmodium
In contrast, there appears to be no evidence for development of mutations in the DHFR gene of P falciparum, point mutations within conserved regions of the DHPS gene confer resistance to sulphonamides. [34] [35] [36] carinii in patients who have received co-trimoxazole or dapsone. 43 In a recent study from the National Institutes In P carinii DHPS is part of a trifunctional protein, along with dihydroneopterin aldolase and hydroof Health, Bethesda, USA the DHFR gene of human derived P carinii was cloned and sequenced, and evixymethyldihydropterin pyrophosphokinase -two other enzymes in the folic acid metabolic pathway. 37 dence of both DHPS and DHFR mutations was sought in 37 isolates of P carinii from 35 patients. 43 Although The first evidence of mutations in the DHPS gene of P carinii came from case reports 38 and a study of 27 15 patients had previously received trimethoprim (in cotrimoxazole), all isolates had identical DHFR sequences patients. 39 Development of resistance was suggested by the finding of non-synonymous single base pair apart from one isolate which had a synonymous polymorphism (which did not result in a substitution of the polymorphisms (point mutations) within a highly conserved region of the DHPS gene of P carinii resulting derived amino acid). By contrast, 16 of 37 samples had non-synonymous DHPS polymorphisms ("mutant" in amino acid substitutions at codons 55 and 57. 39 These amino acid substitutions are at or near to the type DHPS) which was associated with prior use of cotrimoxazole/dapsone prophylaxis. 43 These results sugsulpha binding sites and are homologous to mutations which cause resistance to sulpha drugs in other pathogest that there is less selective pressure from drug exposure on DHFR than on DHPS. Although cogens such as E coli. 40 Mutations in the P carinii DHPS gene were identified in seven of 27 patients and were trimoxazole is routinely given to patients, there is little evidence from animal models of P carinii pneumonia more commonly seen in HIV infected patients with P carinii pneumonia who had failed co-trimoxazole or that the trimethoprim component adds to the efficacy of sulphamethoxazole. 44 45 dapsone prophylaxis. 39 The common "wild type" DHPS of P carinii contains threonine at codon 55 and proline
The drug target of atovaquone is the ubiquinone binding sites in cytochrome b of P carinii. Compared at codon 57. Single mutations are seen with threonine → alanine (codon 55) and proline → serine (codon with co-trimoxazole, atovaquone is used much less commonly for the prophylaxis and treatment of P carinii 57). A "double mutant" exists when both amino acid substitutions occur in the same sample.
pneumonia; however, non-synonymous sequence polymorphisms have been identified in the cytochrome b Although strongly suggestive of sulpha resistance, these data do not prove that the sequence polygene of P carinii from patients with prior exposure to atovaquone. 46 This suggests that P carinii may become morphisms confer drug resistance. 40 Stronger evidence comes from Mei et al who reported two patients who resistant to other drugs. A strategy of reducing or preventing the emergence developed P carinii pneumonia while on co-trimoxazole prophylaxis. 39 Treatment with high dose co-trimoxazole of sulpha resistance in P carinii by using other agents for prophylaxis ("drug switching") is hampered by the was ineffective in one and this patient recovered when treatment was changed to pentamidine. The other availability of other equally effective drugs. The impact of HAART (see below) will certainly reduce the size of patient, despite recovery with co-trimoxazole, had two further episodes of P carinii pneumonia. Both patients the pool of HIV infected patients exposed to sulpha drugs for long periods, but this class of drug will continue had "double mutant" DHPS genes. 39 Helweg-Larsen et al studied bronchoscopic alveolar to be used widely in those patients immunosuppressed by other causes. 2 Prevention of development of atolavage samples from 152 episodes of P carinii pneumonia in 144 patients from a prospective cohort in Copenvaquone resistance in P falciparum is achieved by combining it with proguanil. 46 Perhaps, if atovaquone is hagen, Denmark and assessed, firstly, whether mutations in the DHPS gene of P carinii were associated used for prophylaxis of P carinii pneumonia, it should be combined with another drug such as pyrimethamine with prior exposure to sulpha drugs and, secondly, whether DHPS mutations influenced outcome from P to hinder development of resistance. The sordarins which target fungal translation-elongation factor 2 and carinii pneumonia. 41 A portion of the DHPS gene was analysed using PCR and sequencing; "wild type" P inhibit fungal protein synthesis are active in vitro against a range of fungi 47 and in the animal model of P carinii carinii DHPS was found in 121 episodes (79.6%) and DHPS mutations in 31 episodes (20.4%). 41 The three pneumonia. As yet, the efficacy of sordarins in human P carinii pneumonia has not been studied. month survival was significantly lower in patients with P carinii pneumonia and DHPS containing mutations than in patients with "wild type" DHPS. Factors such as low CD4+ T lymphocyte count, hypoxaemia, and Does azithromycin have activity against P carinii? older age have all been shown to be associated with a poor outcome from P carinii pneumonia. Even after Animal data suggest that macrolide antibiotics, in addition to activity against bacteria and mycobacteria, also adjustment for these prognostic variables, patients with group.bmj.com on July 7, 2017 -Published by http://thorax.bmj.com/ Downloaded from have activity against P carinii. Studies using the animal portunistic infections -including P carinii pneumonia, dMAC, and cytomegalovirus retinitis -admissions to model of P carinii pneumonia (the dexamethasone immunosuppressed rat) also show that combinations hospital, and overall mortality from HIV infection. 52 53 These benefits have occurred over and above that gained of sulphonamide and macrolides (erythromycin, clarithromycin and azithromycin) are active against P by prophylaxis of specific opportunistic infections alone. During the time of these studies the marked reductions carinii and that these combinations are possibly synergistic. 48 in the incidence of opportunistic infections occurred when there was no major change in uptake of prophylaxis In the first introductory article by Dunne et al 49 azithromycin given in a dose of 1200 mg once weekly, by patients, nor were there changes to the US Public Health Service/Infectious Diseases Society of America with or without rifabutin 300 mg daily, was superior to rifabutin alone when given for prophylaxis of disguidelines for the use of prophylaxis to prevent opportunistic infections in patients with HIV infection. 54 seminated Mycobacterium avium complex (dMAC) in a double blind randomised trial of 693 patients with HIV HAART brings about a rapid decrease in plasma HIV RNA and an increase in peripheral blood CD4+ T infection and median CD4+ T lymphocyte counts of <40 cells/ l. Although the study was powered to show lymphocyte counts within a few weeks in most patients.
The resulting "partial immune reconstitution" is shown a difference between treated groups in prevention of dMAC, it also had 80% power to detect a 33% reduction initially by a largely clonal expansion of memory CD4+ T lymphocytes. Subsequently there is death of activated in P carinii pneumonia at a significance level of 0.05. Overall, in this study 185 patients (26.7%) had a pre-CD4+ T lymphocytes and increases in naive CD4+ T lymphocytes are seen with an expansion in the divious episode of P carinii pneumonia at entry. All patients continued their P carinii prophylaxis (co-trimoxazole versity of the T lymphocyte repertoire. It is unclear just how much CD4+ T lymphocyte function is restored by 58.7%, dapsone 18.6%, pentamidine 17%, combinations of drugs 3.3%, none 2.6%) in addition to HAART induced partial immune reconstitution. Some researchers report a return to normal of cell mediated receiving azithromycin alone (233 patients) or with rifabutin (224 patients) or rifabutin alone (236 patients).
immunity against opportunistic pathogens such as cytomegalovirus and Mycobacterium tuberculosis within 3-6 Median follow up was 514 days and 78 patients had 85 episodes of P carinii pneumonia, 48 of which (56%) months of commencing HAART. 56 57 The observation that HAART gives additional prowere first episodes. Twice as many episodes of P carinii pneumonia per 100 patient years were reported in tection over and above that derived from specific prophylaxis for P carinii led several groups to question patients receiving rifabutin alone than in those receiving azithromycin, with or without rifabutin (p=0.008). 49 whether prophylaxis could be safely discontinued in patients who had HAART induced partial immune Two important observations arise from this study. Firstly, the benefit of azithromycin in providing adreconstitution. Results from four observational cohort studies (including the introductory articles by Weverling ditional protection against P carinii pneumonia was seen only in the 508 patients who were taking primary et al 58 and Furrer et al 59 ) and one retrospective case control study provide evidence to support stopping prophylaxis and not in the 185 with a past history of P carinii pneumonia -that is, those receiving secondary primary P carinii prophylaxis in HIV infected patients who have had partial immune reconstitution with prophylaxis. However, the numbers of patients in this subgroup were small so there was insufficient power to HAART.
58-62
The study by Weverling et al 58 was carried out on detect whether there was a true difference. Secondly, the lowest rates of P carinii pneumonia were seen in 7333 HIV infected patients from 52 centres in Europe and Israel who were participating in the EUROSIDA those who received prophylaxis with co-trimoxazole or dapsone. 49 study. The study aimed to describe the incidence of P carinii pneumonia within the EUROSIDA cohort and Interpretation of the study data suggests a possible synergism between azithromycin and sulpha drugs. to see how this had changed with time; it also aimed to describe the incidence of P carinii pneumonia following However, activity from azithromycin alone was demonstrated as, in the patients who did not receive cothe widespread introduction of HAART after July 1996 in those who discontinued P carinii prophylaxis. 58 The trimoxazole or dapsone, fewer cases of P carinii pneumonia were seen in those who received azithromycin overall incidence of P carinii pneumonia fell from 49 cases per 100 person years of follow up before March than in those who received rifabutin. 49 The authors hypothesise that an alternative explanation for their 1995 to 0.3 cases per 100 person years after March 1998. Three hundred and seventy eight patients disobservations might be that rifabutin in fact increases the risk of P carinii pneumonia, although this suggestion continued P carinii prophylaxis after starting HAART; 319 (84%) had received primary prophylaxis and 59 is not borne out by their data as the incidence (attack rate) of P carinii pneumonia was similar in those re-(16%) were receiving secondary prophylaxis. The median CD4+ T lymphocyte count at the time prophylaxis ceiving azithromycin alone and azithromycin with rifabutin. A drug-drug interaction remains a possible was discontinued was 274 cells/ l (primary) and 270 cells/ l (secondary). Overall, the median HIV-1 RNA explanation. Although no experimental data exist for a drug-drug interaction between rifabutin and sulphaload was 500 copies/ml at the time prophylaxis was discontinued. However, 98 patients (26%) discontinued methoxazole or dapsone, there is a significant interaction between rifampicin and dapsone with the former drug P carinii prophylaxis with CD4+ T lymphocyte counts of <200 cells/ l and a median HIV-1 RNA load of 3311 producing a 7-10 fold reduction in dapsone levels, rendering it ineffective. 50 51 copies/ml. In those with CD4+ T lymphocyte counts of <200 cells/ l and an HIV-1 RNA load of <500 copies/ml at the time prophylaxis was discontinued, the withdrawal of prophylaxis occurred a median of eight What is the impact of HAART? Several recent studies have shown that the introduction months (primary) and five months (secondary) after starting HAART. 58 No cases of P carinii pneumonia were of HAART has had a significant impact on the prognosis of patients with HIV infection. These studies have seen during 247 person years of follow up, irrespective of the last CD4+ T lymphocyte count/HIV-1 RNA load shown reductions in the incidence of several opgroup.bmj.com on July 7, 2017 -Published by http://thorax.bmj.com/ Downloaded from at the time of stopping P carinii prophylaxis, the lowest (95% CI 0.0 to 3.2). 61 This patient had been on HAART for 1.7 years and had stopped co-trimoxazole proever (nadir) CD4+ T lymphocyte count before HAART was started, or the duration of HAART. Of note, there phylaxis five months previously. At this time the CD4+ T lymphocyte count had been 216 cells/ l and the were also no cases of cerebral toxoplasmosis and only one case of recurrent bacterial pneumonia was seen, in HIV-1 RNA load was 40 000 cells/ l. The CD4+ T lymphocyte count had fallen to 143 cells/ l at the time of a patient with a CD4+ T lymphocyte count of >300 cells/ l. 58 presentation with P carinii pneumonia. For two months before developing P carinii pneumonia this patient had The study by Furrer et al from the Swiss HIV cohort included patients from seven treatment centres. 59 Two received G-CSF. The anti-inflammatory effects of G-CSF may well have contributed to the occurrence of P hundred and sixty three patients receiving P carinii prophylaxis who had sustained increases in CD4+ T carinii pneumonia in this case. 61 Rodriguez-Guardado et al retrospectively compared lymphocyte counts to >200 cells/ l or a CD4+:total lymphocyte ratio of >14% for three months or more HIV infected patients who had evidence of HAART induced partial immune reconstitution with rises in after starting HAART were included in the study. The primary end point was development of P carinii pneu-CD4+ T lymphocyte counts to >200 cells/ l. 62 Twenty six patients discontinued prophylaxis against P carinii monia and the secondary end point was development of cerebral toxoplasmosis. The median CD4+ T pneumonia and 27 continued prophylaxis. The two groups were similar in terms of HIV risk factor, type of lymphocyte count at entry was 325 cells/ l and the median nadir count had been 110 cells/ l. No P carinii prophylaxis and regimens of HAART, and mean CD4+ T lymphocyte count. In those who stopped prophylaxis pneumonia or cerebral toxoplasmosis occurred during the follow up period (median 11.3 months, range 3.0 the mean CD4+ T lymphocyte count was 310 (range 216-486) cells/ l. Cases were followed for a mean of -18.8). Nine patients resumed prophylactic treatment, because the CD4+ T lymphocyte count fell to <200 291 days; no cases of P carinii pneumonia were seen.
On the basis of these data the United States Public cells/ l in seven cases, because of recurrent bacterial chest infection in one, and in one for personal reasons.
Health Service/Infectious Diseases Society of America now recommend that primary prophylaxis can be safely The study by Schneider et al 60 from Utrecht, Netherlands examined the incidence of P carinii pneumonia discontinued in patients responding to HAART with sustained increases in CD4+ T lymphocyte counts after discontinuation of prophylaxis (both primary and secondary) if CD4+ T lymphocyte counts were >200 above 200 cells/ l. 10 The guidelines acknowledge, firstly, that data to support the recommendations come largely cells/ l documented on two occasions at least one month apart after starting HAART. The study end from patients who began HAART which included a protease inhibitor, secondly, that the median follow up point was development of P carinii pneumonia. Seventy eight patients discontinued prophylaxis (primary=62 was 6-12 months and the median CD4+ T lymphocyte count at the time prophylaxis was discontinued was patients) at which time their median CD4+ T lymphocyte count was 347 cells/ l. Their median nadir count >300 cells/ l and, thirdly, that many of the patients who discontinued prophylaxis had a sustained suppression before starting HAART was 79 cells/ l. HIV-1 RNA was not detectable in 61 patients and was 15 000 copies/ of HIV-1 RNA load to below detection limits of available assays.
10 ml in the other 17. Prophylaxis was discontinued at a mean (SD) of 9.8 (6.4) months after starting HAART. What if, despite HAART, CD4+ T lymphocyte counts fall below 200 cells/ l and/or HIV-1 RNA inNo patients developed P carinii pneumonia during mean (SD) follow up of 12.7 (7.8) months. 60 creases again? Current recommendations are that, in the absence of data from prospective observational studIn December 1997 guidelines for discontinuing prophylaxis were changed at four major AIDS centres in ies or randomised trials, the same criteria should be used as for starting primary P carinii prophylaxis (see Denmark. Kirk et al studied 219 consecutive patients who stopped P carinii prophylaxis (primary prophylaxis above). 10 Implicit in these recommendations is the need for close patient monitoring to detect rapidly any fall in in 193 patients) when their CD4+ T lymphocyte counts rose above 200 cells/ l for more than six months in CD4+ T lymphocyte count or increase in HIV-1 RNA load which identify recurrence of a risk of P carinii response to HAART. 61 As a group, the mean nadir CD4+ T lymphocyte had been 117 cells/ l (primary pneumonia in individual patients. In this situation P carinii pneumonia must be considered in the differential prophylaxis) and <50 cells/ l (secondary prophylaxis). One person developed P carinii pneumonia after 174 diagnosis for every patient presenting with respiratory symptoms. person years of follow up, an overall incidence of P carinii pneumonia of 0.6 cases per 100 person years There are no data to support discontinuation of sec-LEARNING POINTS * Co-trimoxazole 960 mg once daily is the regimen of choice for prophylaxis of P carinii pneumonia in both HIV infected and non-HIV infected immunosuppressed individuals * Long term use of co-trimoxazole as prophylaxis is associated with development of resistance in bacteria * Drug resistance may be developing in P carinii * Primary prophylaxis of P carinii pneumonia may be discontinued in patients responding to HAART with sustained increases in CD4+ T lymphocyte counts of >200 cells/ l. If CD4+ T lymphocyte counts fall again despite HAART, primary prophylaxis should be restarted
